The disclosure is directed to novel predictive methods and personalized therapies for treating psoriatic arthritis (PsA). Specifically, this disclosure relates to methods of treating a patient having PsA by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the PsA patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods useful in predicting the likelihood that a patient having PsA will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.本揭示內容係關於用於治療亁癬性關節炎(PsA)之新穎預測性方法及個別化療法。具體而言,本揭示內容係關於基於PsA患者傾向於對使用IL-17拮抗劑(例如,IL-17抗體,例如蘇金單抗(secukinumab))之治療具有有利反應藉由向該PsA患者選擇性投與該IL-17拮抗劑來治療該患者之方法。本文亦揭示用於預測PsA患者將對使用IL-17拮抗劑(例如,IL-17抗體,例如蘇金單抗)之治療具有反應之可能性之診斷方法。
